Convergence and Personalized Medicine
Greg Yap is Senior Vice President and Lifecycle Leader for
Advanced Staining Assays at Ventana Medical Systems.
In this role, Greg is responsible for Ventana’s 450 million dollar cancer diagnostic testing business. Ventana’s tests are the market leaders and are used to help guide treatment for over 6 million cancer patients each year worldwide. Previously, Greg was Chief Operating Officer at Cellective Dx, a circulating tumor cell company, and held multiple senior operating roles at Affymetrix.
Washington Update from Congressman Paul Gosar DDS
Congressman Paul Gosar (AZ-4th District) is a health care provider and small business owner who is focused on bringing jobs back to the district, reforming health care, reining in government spending and ensuring that his constituents are involved in the solution process. Congressman Paul Gosar serves on the House Committee on Oversight and Government Reform including as the Vice Chairman of the House Subcommittee on Energy Policy, Health Care, and Entitlements which has oversight over federal health care policy, food and drug safety, energy policy, solvency of federal entitlement programs. He also serves on the Subcommittee on Economic Growth, Job Creation, and Regulatory Affairs which has oversight jurisdiction regulatory affairs, impediments to economic growth and job creation, monetary policy, banking, infrastructure, and tax policy as well as the Subcommittee on National Security which has Oversight jurisdiction over national security, homeland security, foreign operations, immigration, emergency management, and criminal justice.
Leadership Insights - Panel
Heather Morel, VP/GM McKesson Specialty Health, Dr. Jeffrey Trent, CEO and Chief Scientific Officer, TGen, Michele Y. Halyard, M.D, vice dean, Mayo Medical School – Arizona Campus, Dr. Ronald Korn, Medical Director, Virginia G. Piper cancer Center.
Paul Keim, Phd - 2012 Bioscience Researcher of the Year
Dr. Paul Keim is the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), the Director of Pathogen Genomics at the Translational Genomics Research Institute (TGen) and research affiliate at Los Alamos National Laboratory (LANL).
Dr. Keim’s research focuses on the advancement of forensics and genomics analysis of bacterial pathogens. You may know this globally recognized researcher as ” Doctor Anthrax” (a moniker he gained after 9-11) but there is a lot more to the work Dr. Keim and his team focus on every day.
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches.Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award.
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona
- Bob Bosserman, CEO, Medelis
- Janet Spear, Plant Manager, Celgene
- Joan Koerber-Walker, president & CEO, AZBio (moderator)
- Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley
- Dr. Phil Miller, Ventana
2012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day.Critical Path Institute, a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does.C-Path Milestones and “firsts” include:
- 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely.
- 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data.
- 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes.
- 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials.
- 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials.
2012 State of the Industry: John D. Carroll of FierceBiotech
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered virtually every aspect of the global drug development industry over the past decade. His work includes the popular Fierce 15, which recognizes the most innovative private companies in the business each year. His daily reports keep more than 100,000 subscribers around the world clued in to the latest developments on deals, data and industry trends. Carroll plans to address the biggest influences affecting the fast-changing biopharma industry and what it means to biotech executives in Arizona.
AZBio Public Service Award - Rick Myers
A widely respected and tireless civic leader, Rick Myers is a visionary and a strong advocate for promoting the biosciences in Arizona. Rick serves as the Governor-appointed Chair for the Arizona Board of Regents and advocates for growing the research enterprise and promoting biosciences.
In 2012, Regent Myers was honored with the 2012 AZBio Public Service Award.